Bozkurt Ceyhun, Ertem Ulya, Oksal Aysegül, Sahin Gürses, Yüksek Nazmiye, Birgen Dilek
Department of Pediatric Oncology and Pathology, Dr. Sami Ulus Children's Hospital, Ankara, Turkey.
Pediatr Hematol Oncol. 2008 Sep;25(7):621-9. doi: 10.1080/08880010802313657.
Matrix metalloproteinases (MMP) are enzymes involved in the reconfiguration of the microenvironment by means of degrading the extracellular matrix and have more than 20 subgroups containing zinc. Proteins that serve as the inhibitors of these enzymes are called tissue inhibitors of matrix metalloproteinase (TIMP). These enzymes have been shown to be active in a wide range of processes, from wound recovery to fetus development, heart diseases, and spread of malignant diseases. The aim of this study was to investigate whether there is a relationship between the type, stage, and prognosis of childhood lymphoma subjects and matrix metalloproteinase type-9 (MMP-9) and its inhibitor, tissue inhibitor of matrix metalloproteinase type-1 (TIMP-1). Paraffin blocks of childhood patients diagnosed with non-Hodgkin lymphoma (n = 23), Hodgkin lymphoma (n = 14), or reactive lymphadenopathy (n = 12) were retrospectively immunohistochemically stained with MMP-9 and TIMP-1 stains and whether there was a relationship between the degree of staining and the type, tumor stage, and prognosis of the disease was investigated. Moderate and high degrees of MMP-9 staining were detected in 94.6% of the lymphoma patient tissues and a slight TIMP-1 staining was detected in 21.6% of the lymphoma patient tissues. No relationship was observed between the degree of these staining patterns and the type, tumor stage, and prognosis of the disease. This study indicates that the equilibrium between MMP-9 and TIMP-1 is important in lymphomas in addition to all the physiological and pathologic events although MMP-9 and the TIMP-1 staining patterns are not related to the tumor stage, prognosis, and type of the disease. Larger series of patients are needed to determine the prognostic value of MMP-9 and TIMP-1 in childhood lymphoma.
基质金属蛋白酶（MMP）是一类通过降解细胞外基质参与微环境重塑的酶，有20多个含锌的亚群。作为这些酶抑制剂的蛋白质被称为基质金属蛋白酶组织抑制剂（TIMP）。这些酶已被证明在从伤口愈合到胎儿发育、心脏病以及恶性疾病扩散等广泛过程中具有活性。本研究的目的是调查儿童淋巴瘤患者的类型、分期和预后与基质金属蛋白酶9型（MMP-9）及其抑制剂基质金属蛋白酶组织抑制剂1型（TIMP-1）之间是否存在关联。对诊断为非霍奇金淋巴瘤（n = 23）、霍奇金淋巴瘤（n = 14）或反应性淋巴结病（n = 12）的儿童患者的石蜡块进行回顾性免疫组织化学染色，用MMP-9和TIMP-1染色剂染色，并研究染色程度与疾病类型、肿瘤分期和预后之间是否存在关联。在94.6%的淋巴瘤患者组织中检测到中度和高度的MMP-9染色，在21.6%的淋巴瘤患者组织中检测到轻微的TIMP-1染色。未观察到这些染色模式的程度与疾病类型、肿瘤分期和预后之间存在关联。本研究表明，尽管MMP-9和TIMP-1的染色模式与疾病的肿瘤分期、预后和类型无关，但MMP-9和TIMP-1之间的平衡在淋巴瘤以及所有生理和病理事件中都很重要。需要更大规模的患者系列来确定MMP-9和TIMP-1在儿童淋巴瘤中的预后价值。
